The biopharma industry is currently navigating a complex landscape marked by significant financial developments and technological advancements. Recent financial reports from key players like Moderna and Gilead Sciences, coupled with the growing use of artificial intelligence (AI) in clinical
The victory of Donald Trump in the U.S. presidential election has sparked widespread speculation about the potential changes within federal health agencies, particularly the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). Trump's past and potential future choices for
In a significant move just three years post its highly successful IPO, Sana Biotechnology has announced a strategic restructuring that will likely reshape the company's future and impact. This overhaul will include layoffs and a refocused research directive, marking a notable shift in priorities
The pharmaceutical industry has long been a battleground for innovation, with companies around the globe constantly striving to outpace each other in developing cutting-edge therapies. Oncology, the branch of medicine that deals with cancer, has emerged as a focal point of this dynamic competition.
The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of
Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step
